MK-0954E Study in Participants With Hypertension (MK-0954E-357)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 327 participants.

Also called NCT01302691

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 327 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01302691
Main results
  • Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg Hypertension research : official journal of the Japanese Society of Hypertension, 2015-05 DOI, PubMed 25716649

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01302691. Randomized; double masking; primary purpose treatment. Start 2011-01-01 (actual); primary completion 2012-04-01 (actual). Results posted on 2017-01-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
Condition
Hypertension
Intervention (Drug)
losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
Intervention (Drug)
Losartan potassium
Intervention (Drug)
Amlodipine besylate
Intervention (Drug)
Placebo to MK-0954E
Intervention (Drug)
Placebo to losartan potassium
Intervention (Drug)
Placebo to amlodipine besylate
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01302691
Content hash
4a1fa0107e9182c7d37817502fbcebc6a9f06603611717c741c91c1cdbd0fe17